Reviva announces positive full dataset for 1-year phase 3 recover open label extension study evaluating brilaroxazine in schizophrenia

– robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms – – generally well-tolerated with low rates of adverse events and discontinuation – – brilaroxazine improved multiple neuroinflammatory markers reported to enhance efficacy and mitigate side effects – – virtual investor webcast today at 8:00 a.m. edt – cupertino, calif.
RVPH Ratings Summary
RVPH Quant Ranking